

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-138)

TIDUTAMAB

PRONUNCIATION

tye due' ta mab

THERAPEUTIC CLAIM

Antineoplastic; Immunomodulator

## CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human CD3 antigen) (human-Mus musculus monoclonal XmAb18087  $\gamma$ 1-chain), (265→231'),(268→234')-bis(disulfide) with immunoglobulin G1, anti-(human somatostatin receptor 2) (human-Mus musculus monoclonal XmAb18087  $\gamma$ 1-chain) disulfide with human-Mus musculus monoclonal XmAb18087  $\kappa$ -chain
2. Immunoglobulin half-G1-kappa/scFv-h-CH2-CH3, anti-(*Homo sapiens* Somatostatin receptor type 2 (SSTR2, SRIF-1)) and anti-(*Homo sapiens* T-cell surface glycoprotein CD3 epsilon chain (T-cell surface antigen T3/Leu-4 epsilon chain, CD3e antigen)), monoclonal antibody, bispecific;  $\gamma$ 1 heavy chain anti-SSTR2 (1-451) [VH (*Homo sapiens* IGHV3-48\*03 (91%) –(IGHD)-IGHJ4\*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1\*03 {CH1[N<sup>91</sup>>D(213)], R<sup>97</sup>>K(219)] CH2[E<sup>3</sup>>P(238),L<sup>4</sup>>V(239),L<sup>5</sup>>del,G<sup>6</sup>>A(240),S<sup>37</sup>>K(271),Q<sup>65</sup>>E(299)],CH3[L<sup>28</sup>>D(372),K<sup>30</sup>>S(374),N<sup>44</sup>>D(388),Q<sup>78</sup>>E(422),N<sup>81</sup>>D(425)]] (123-451)], (225-219')-disulfide with  $\kappa$  light chain anti-SSTR2 (1'-219') [V-KAPPA (*Homo sapiens* IGKV4-1\*01 (92%) –IGKJ4\*01)] [12.3.8] (1'-112') -*Homo sapiens* IGKC\*01 (113'-219')]; heavy chain scFv-h-CH2-CH3, anti-CD3E (1"-485") [VH (*Homo sapiens* IGHV3-73\*01 (87%) –(IGHD)-IGHJ6\*01 (91%)) [8.10.16] (1"-125") tetrakis(glycyllysylprolylglycylseryl)-linker (126"-145") [V-LAMBDA (*Mus musculus* IGLV1\*01 (81%) –IGLJ1\*01/*Homo sapiens* IGLV7-46\*01 (77%) –IGLJ3\*02) [9.3.9] (146"-254")]-*Homo sapiens* IGHG1\*03 {CH1-del, h[C<sup>5</sup>>S(259")], CH2[E<sup>3</sup>>P(272"),L<sup>4</sup>>V(273") L<sup>5</sup>>del,G<sup>6</sup>>A(274"), S<sup>37</sup>>K(305")], CH3[E<sup>17</sup>>Q(395"),S<sup>24</sup>>K(402")]]]; (255"-485") (231-265":234-268")-bisdisulfide

## STRUCTURAL FORMULA

### Heavy chain anti-SSTR2

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	DYGMAWFRQA	PGKGLEWVSF	50
ISNLGYSIYY	ADSVKGRFTI	SRDNAKNSLY	LQMNSLRAED	TAVVYCARAP	100
YDYSDFDPM	YWGQGLVTV	SSASTKGPSV	FPLAPSSKST	SGGTAALGCL	150
VKDYFPEPVT	VSWNSGALTS	GVHTFPAVLQ	SSGLYSLSV	VTVPSSSLGT	200
QTYICNVNHK	PSDTKVDKVV	EPKSCDKTHT	CPPCPAPPVA	GPSVFLFPPK	250
PKDTLMISRT	PEVTCVVVDV	KHEDPEVKFN	WYVDGVEVHN	AKTKPREEEY	300
NSTYRVVSVL	TVLHQDWLNG	KEYKCKVSNK	ALPAPIEKTI	SKAKGQPREP	350
QVYTLPPSRE	EMTKNQVSLT	CDVSGFYPSD	IAVEWESDQ	PENNYKTPPP	400
VLDSGDSFFL	YSKLTVDKSR	WEQGDVFS	VMHEALHNHY	TQKSLSLSPG	450
K					451

### Light chain anti-SSTR2

DIVMTQSPDS	LAVSLGERAT	INCKSSQSL	NSRNRKNYLA	WYQQKPDQSP	50'
KLLIYWASTR	ESGVDFRFSG	SGSGTDFTLT	ISSLQAEDVA	VYYCKQSYL	100'
WTFGGGTKVE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVVCL	LNNFYPREAK	150'
VQWQVDNALQ	SGNSQESVTE	QDSKDYSTYSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSPV	TKSFNRGEC				219'

Heavy chain "assembly" anti-CD3E

EVQLVESGGG	LVQPGGSLRL	SCAASGFTFS	TYAMNWRQA	PGKGLEWVGR	50"
IRSKYNNYAT	YYADSVKGRF	TISRDDSKNT	LYLQMNSLRA	EDTAVYYCVR	100"
HGNFGDSYVS	WFAYWQGTL	VTVSSGKPGS	GKPGSGKPGS	GKPGSQAVVT	150"
QEPSLTVSPG	GTVTLTCGSS	TGAVTTSNYA	NWVQKPGKS	PRGLIGGTNK	200"
RAPGVPARFS	GSLLGKKAAL	TISGAQPEDE	ADYYCALWYS	NHWVFGGGTK	250"
LTVLEPKSSD	KTHTCPPCPA	PPVAGPSVFL	FPPKPKDTLM	ISRTPEVTCV	300"
VVDVKHEDPE	VKFNWYVDGV	EVHNAKTKPR	EEQYNSTYRV	VSVLTVLHQD	350"
WLNKKEYKCK	VSNKALPAPI	EKTISKAKGQ	PREPQVYTLF	PSREQMTKNQ	400"
VKLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	SFFLYSKLTV	450"
DKSRWQQGNV	FSCSVMHEAL	HNHYTQKSLS	LSPGK		485"

Disulfide bridges

22-96	22"-98"	23'-94'	139"-199"	149-205	167"-235"	219"-225"
231-265"	234-268"	265-325	299"-359"	371-429	405"-463"	

Glycosylation sites (N)

Asn-301 Asn-335"

MOLECULAR FORMULA	C <sub>5633</sub> H <sub>8660</sub> N <sub>1504</sub> O <sub>1740</sub> S <sub>38</sub> , (non-glycosylated)
MOLECULAR WEIGHT	126.51 kDa
TRADEMARK	None as yet
SPONSOR	Xencor Inc.
CODE DESIGNATIONS	XmAb18087
<u>CAS</u> REGISTRY NUMBER	2148354-90-7
UNII	88635FW2QX
WHO NUMBER	11022

gbk